Basic research yields knowledge of transcription factor binding sites

New, robust methodology is side benefit

HUNTSVILLE, Ala. --Whether or not a gene is expressed, that is, whether it is turned on or turned off, is in part controlled by a group of proteins called transcription factors. Scientists in the Myers lab at the HudsonAlpha Institute recently published results of a basic research project undertaken to better understand mechanisms that determine cell type-specific transcription factor binding.

HudsonAlpha sequencing 500 trio exomes to elucidate rare genetic disorders under CSER grant

News Outlet: 
Genome Web Clinical Sequencing News
Date published: 
September 18, 2013

The HudsonAlpha Institute for Biotechnology has embarked on a research project to analyze the genomes of 500 children with unexplained genetic disorders and their parents in order to provide at least some families with a molecular diagnosis.

Recap of Rocket City Science Cafe featuring Jian Han, M.D., Ph.D.

News Outlet: 
The Huntsville Times,
Date published: 
September 3, 2013
HUNTSVILLE, Alabama - Doctors are probably asking the wrong question when they wonder "what caused your disease," human genetics researcher and entrepreneur Dr. Jian Han said Tuesday night. According to Han, a better question might be, "What is your immune system doing today?"
Han, a research scientist at theHudsonAlpha Institute for Biotechnology and founder of several private companies, explained his theory of disease diagnosis to scientifically curious locals attending the second monthly meeting of Huntsville's new Rocket City Science Café.

HudsonAlpha guidebook featured in national education publication

“Too new for textbooks,” means timely and exciting content for life sciences classrooms

American Biology Teacher, a print and online journal for K-16 biology teachers, features HudsonAlpha’s Biotechnology Discoveries and Applications guidebook in the September issue.

HudsonAlpha and UAB researchers team to identify lupus disease pathways

Study of the epigenome searches for disease triggers

Using genome-wide analyses, researchers at the HudsonAlpha Institute for Biotechnology along with clinical and research partners at the University of Alabama at Birmingham, have released the largest published study that examines epigenetic risk pathways for lupus. Lupus is an autoimmune disease that occurs primarily in women and is known to have both genetic and epigenetic causes. The disease may affect various parts of the body, especially the skin, joints, blood and kidneys.

Kailos Genetics approved to test human DNA for personalized medicine, feature

News Outlet: 
The Huntsville Times,
Date published: 
August 12, 2013
HUNTSVILLE, Alabama – Huntsville biotechnology company Kailos Genetics is expanding its capabilities in the emerging science of personal medicine in a move to grow both the company and Huntsville’s biotechnology sector.
“All of the underpinnings are there” for biotech to join space and defense as key foundations of Huntsville’s economy, Kailos Chief Strategy Officer Mike Walters said in an Aug. 6 interview at the company's laboratories in the HudsonAlpha Institute for Biotechnology.

iRepertoire and Sequenta join forces on blood cancer testing

News Outlet: 
Business Wire
Date published: 
August 7, 2013
SOUTH SAN FRANCISCO, Calif. and HUNTSVILLE, Ala. -- Sequenta and iRepertoire announced today that Sequenta has gained exclusive rights to the iRepertoire intellectual property on novel methods of immune cell sequencing for minimal residual disease (MRD) testing. This intellectual property complements Sequenta’s existing patents on MRD, including its proprietary LymphoSIGHT™ technology. The agreement reinforces Sequenta’s patent portfolio, which strengthens Sequenta’s ability to provide future products and new features and solidifies the company’s position as the MRD market leader.

Diatherix Laboratories acquires diagnostic testing patent

News Outlet: 
PRNewswire, GenomeWeb Daily News
Date published: 
August 6, 2013
Huntsville, Ala. -- DIATHERIX Laboratories, Inc., today announced that it has acquired the patent to Tem-PCR, a diagnostic testing technology that allows for rapid identification of multiple infectious disease organisms. The acquisition from QIAGEN, a leading global provider of molecular sample and assay technologies, follows a multi-year agreement through which DIATHERIX licensed Tem-PCR from QIAGEN. Terms of the deal were not disclosed.

Serina announces partnership with Scripps Research Institute for drug development

HUNTSVILLE, Ala. -- Serina Therapeutics announced today that the company has entered into a research agreement with the Scripps Research Institute for development of polymer-antibody drug conjugates. 

HudsonAlpha and UAB researchers work to identify optimal treatments for the most common form of breast cancer

Komen funds collaborative effort using tumor genomics to identify effective treatments

HUNTSVILLE, Ala. – The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year.  Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.

Syndicate content